Brasacchio Daniella, Okabe Jun, Tikellis Christos, Balcerczyk Aneta, George Prince, Baker Emma K, Calkin Anna C, Brownlee Michael, Cooper Mark E, El-Osta Assam
Epigenetics in Human Health and Disease Laboratory, The Alfred Medical Research and Education Precinct, Baker IDI Heart and Diabetes Institute, Victoria, Australia.
Diabetes. 2009 May;58(5):1229-36. doi: 10.2337/db08-1666. Epub 2009 Feb 10.
Results from the Diabetes Control Complications Trial (DCCT) and the subsequent Epidemiology of Diabetes Interventions and Complications (EDIC) Study and more recently from the U.K. Prospective Diabetes Study (UKPDS) have revealed that the deleterious end-organ effects that occurred in both conventional and more aggressively treated subjects continued to operate >5 years after the patients had returned to usual glycemic control and is interpreted as a legacy of past glycemia known as "hyperglycemic memory." We have hypothesized that transient hyperglycemia mediates persistent gene-activating events attributed to changes in epigenetic information.
Models of transient hyperglycemia were used to link NFkappaB-p65 gene expression with H3K4 and H3K9 modifications mediated by the histone methyltransferases (Set7 and SuV39h1) and the lysine-specific demethylase (LSD1) by the immunopurification of soluble NFkappaB-p65 chromatin.
The sustained upregulation of the NFkappaB-p65 gene as a result of ambient or prior hyperglycemia was associated with increased H3K4m1 but not H3K4m2 or H3K4m3. Furthermore, glucose was shown to have other epigenetic effects, including the suppression of H3K9m2 and H3K9m3 methylation on the p65 promoter. Finally, there was increased recruitment of the recently identified histone demethylase LSD1 to the p65 promoter as a result of prior hyperglycemia.
These studies indicate that the active transcriptional state of the NFkappaB-p65 gene is linked with persisting epigenetic marks such as enhanced H3K4 and reduced H3K9 methylation, which appear to occur as a result of effects of the methyl-writing and methyl-erasing histone enzymes.
糖尿病控制与并发症试验(DCCT)、后续的糖尿病干预与并发症流行病学(EDIC)研究以及最近的英国前瞻性糖尿病研究(UKPDS)结果显示,在常规治疗和强化治疗的患者中出现的有害终末器官效应,在患者恢复到常规血糖控制水平后仍持续存在超过5年,这被解释为过去高血糖的遗留效应,即“高血糖记忆”。我们推测短暂性高血糖介导了归因于表观遗传信息变化的持续性基因激活事件。
通过可溶性NFκB-p65染色质的免疫纯化,利用短暂性高血糖模型将NFκB-p65基因表达与由组蛋白甲基转移酶(Set7和SuV39h1)和赖氨酸特异性去甲基化酶(LSD1)介导的H3K4和H3K9修饰联系起来。
环境性或既往高血糖导致的NFκB-p65基因持续上调与H3K4m1增加有关,但与H3K4m2或H3K4m3无关。此外,葡萄糖还显示出其他表观遗传效应,包括抑制p65启动子上的H3K9m2和H3K9m3甲基化。最后,既往高血糖导致最近鉴定出的组蛋白去甲基化酶LSD1向p65启动子的募集增加。
这些研究表明,NFκB-p65基因的活跃转录状态与持续的表观遗传标记有关,如增强的H3K4和减少的H3K9甲基化,这似乎是由于甲基写入和甲基擦除组蛋白酶的作用而发生的。